Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma

Table 1 Clinical study of intrahepatic cholangiocarcinoma

Ref.	n	Survival rate (%)	MST (mo)	Prognostic factor
Marubashi et al[6]	111	59.7 (3 yr)	-	IM, Hilar inv, LN
Guglielmi et al[7]	145	-	19 (LN+), 42 (LN-)	LNR > 0.25, LN
Zhu et al[8]	37	-	-	CA19-9, Low prealbmin
Dhanasekaran et al[9]	105	-	16	V
Wang et al[10]	367	-	-	CEA, CA19-9, Size, V
De Rose et al[11]	79 (MF)	-	-	Doubling time < 70 d
Sulpice et al[12]	87	-	-	BT, Maj, Size, V, IM
Ribero et al[13]	434	39.8 (5 yr)	-	LN, CA19-9, IM
Liu et al[14]	132	-	-	Por, CA19-9, Dis(-)
Uchiyama et al[15]	334	-	-	Shown in Table 2
Chen et al[16]	64	32 (3 yr)	-	LN, PN, Size
Uno et al[17]	273	-	-	Shown in Table 2
Morine et al[18]	22	-	-	Shown in Table 2
Jiang et al[19]	102	-	-	CA19-9, IM
Murakami et al[20]	44	47 (5 yr)	-	LN
Clark et al[21]	4893	8.4 (5 yr, LN+)	-	LN
		25 (5 yr, LN-)
de Jong et al[22]	449	31 (5 yr)	27	IM, V, LN
Li et al[23]	115	-	-	Cirrhosis
Chen et al[24]	320	-	-	-

MST: Median survival time; Prognostic factor: Factor for poor prognosis; IM: Multiple tumors or intrahepatic metastasis; Hilar inv: Hilar invasion; LN: Lymph node metastasis; LNR: Rate of the positive lymph node metastasis; CA19-9: Elevated serum carbohydrate antigen 19-9; CEA: Elevated serum carcinoembryonic antigen; Size: Larger tumor size; V: Vascular invasion; BT: Blood transfusion during operation; Dis: Lymph node dissection; PN: Perineural invasion.